Taro Pharmaceuticals

Taro Pharmaceuticals

TARO
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Taro Pharmaceuticals is a mission-driven generic drug manufacturer focused on providing affordable, high-quality medications, with a recognized leadership position in topical dermatology. Its strategic achievements include successful integration into Sun Pharma's global network, providing R&D and financial scale, and the expansion of its product portfolio into high-volume therapeutic areas like cardiology. The company's strategy centers on leveraging its complex formulation platform to differentiate its generic offerings and capitalize on stable market demand for cost-effective therapeutics.

DermatologyCardiologyNeurology

Technology Platform

A platform centered on complex formulation science, bioequivalence testing, and robust manufacturing processes for generic topical dermatological products and oral solid dosage forms.

FDA Approved Drugs

47
ACETAMINOPHEN AND IBUPROFENANDAJan 2, 2026
PERAMPANELANDANov 25, 2025
RIVAROXABANANDAOct 7, 2025

Opportunities

The company is positioned to capitalize on sustained demand for affordable generics, the high-value niche of complex topical dermatology with less price erosion, and the large, chronic therapeutic markets of cardiology and neurology through its expanding oral solid dosage portfolio.
Integration with Sun Pharma provides a vast pipeline and cost advantages.

Risk Factors

Key risks include intense industry-wide price erosion for generic drugs, significant regulatory and compliance challenges for manufacturing facilities, dependency on a limited number of key products subject to patent litigation, and strategic dependence on parent company Sun Pharma's priorities.

Competitive Landscape

Taro competes in dermatology against specialized generic firms like Perrigo, where its formulation expertise is a moat. In oral solids, it faces intense price competition from large global generics players (Teva, Viatris) and low-cost manufacturers. Its integration with Sun Pharma provides cost and supply chain advantages.